Here’s Why British American Tobacco plc Offers More Long-Term Value Than Imperial Tobacco Group plc & AstraZeneca plc!

British American Tobacco plc (LON:BATS), Imperial Tobacco Group plc (LON:IMT) & AstraZeneca plc (LON:AZN) are under the spotlight.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

British American Tobacco (LSE: BATS) said today that it had acquired TDR and other tobacco/retail assets from Croatia’s Adris Grupa for a total enterprise value of €550m — news of which helped its stock outperform the broader market. 

BATS remains a solid buy, but are your savings better invested in British American Tobacco than in two defensive names such us Imperial Tobacco (LSE: IMT) and AstraZeneca (LSE: AZN) if you are after long-term value? 

Here are some of the answers you might be looking for. 

BATS Offers A Good Entry Point For Value Hunters

In BATS’ size resides its strength.  

The bolt-on deal announced today signals that the tobacco maker is paying more attention to inorganic growth — after all, sales in 2017 are expected to come in just line with those that the tobacco behemoth reported in 2009.

Hefty operating profits need a steeper growth rate to render its stock more appealing to value investors although, at 18x 2016 net earnings, BATS doesn’t strike me as being particularly expensive. The stock is flat since early June 2014, but at 3,627p a share you’d do well to add exposure with the aim to record a steady income from dividends — its rich dividend policy promises a yield north of 4% over the next three years — and some capital appreciation. 

Imperial’s recent strength on the stock exchange is another reason why it may be a good time to invest in BATS. 

Imperial Tobacco: The Valuation Gap Has Now Officially Closed 

I am not puzzled by Imperial Tobacco’s rally, but I think that most of its recent gains (+20% year to date, +26% over the last 12 months) should be attributed to takeover talk rather than significantly improved fundamentals, or trading multiples pointing to value.

In fairness, its acquisitive strategy should be praised — Imperial is acquiring four bands that Reynolds American must sell following its purchase of smaller rival Lorillard — but its relative valuation, based on forward earnings and core cash flows, has caught up with that of BATS over the last five weeks of trade (this excludes multiples for book value, according to which BATS still commands a meaningful premium).

True, BATS could be oversold because it seems to lack strategic options, while Imperial Tobacco remains the chief takeover target in the industry — but anyone betting solely on that element will end up being hugely disappointed as soon as this year, in my view. 

AstraZeneca: Bad News…

Astra’s own estimates for revenues and earnings are incredibly bullish for the next few years, yet mainly bad news has drawn my attention in recent times. Of particular interest in recent days was Amgen’s detailed decision to dump the Astra-partnered psoriasis antibody brodalumab, due to risk of suicide. 

As Jacob Plieth at EP Vantage recently wrote, “it is highly unusual for a discontinuing partner to spell out in such detail the reasons for pulling out, suggesting that the problem is very serious, and that this is not just an excuse to get Amgen out of funding development.” Mr Plieth also noted that in its defence against Pfizer’s takeover attempt last year the group “trumpeted the potential of brodalumab as an underappreciated asset that could bring in $0.5-1.5bn of peak revenues.

My take is that Astra should be considered by value investors only if its stock dropped to 3,100p-3,400p from its current level of 4,400p, and that’s based on several elements — including the fair value of its assets, its pipeline of drugs, fundamentals, forward multiples and better alternative choices in the pharma space, such as Shire, for instance. The upbeat headline from Reuters today —“AstraZeneca: boosted by positive lung cancer drug update” — did little to lift spirits, with its stock up only 0.6% at the time of writing. 

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Alessandro Pasetti has no position in any shares mentioned. The Motley Fool UK has no position in any of the shares mentioned. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Investing Articles

Are these the best stocks to buy on the FTSE right now?

With the UK stock market on the way to hitting new highs, this Fool is considering which are the best…

Read more »

Petrochemical engineer working at night with digital tablet inside oil and gas refinery plant
Investing Articles

Can the Centrica dividend keep on growing?

Christopher Ruane considers some positive factors that might see continued growth in the Centrica dividend -- as well as some…

Read more »

Smiling family of four enjoying breakfast at sunrise while camping
Investing Articles

How I’d turn my £12,000 of savings into passive income of £1,275 a month

This Fool is considering a strategy that he believes can help him achieve a stable passive income stream with a…

Read more »

Person holding magnifying glass over important document, reading the small print
Investing Articles

2 top FTSE 250 investment trusts trading at attractive discounts!

This pair of discounted FTSE 250 trusts appear to be on sale right now. Here's why I'd scoop up their…

Read more »

Smiling young man sitting in cafe and checking messages, with his laptop in front of him.
Investing Articles

3 things that could push the Lloyds share price to 60p and beyond

The Lloyds share price has broken through 50p. Next step 60p? And then what? Here are some thoughts on what…

Read more »

Young female business analyst looking at a graph chart while working from home
Investing Articles

£1,000 in Rolls-Royce shares a year ago would be worth this much now

Rolls-Royce shares have posted one of the best stock market gains of the past 12 months. But what might the…

Read more »

Investing Articles

Are HSBC shares a FTSE bargain? Here’s what the charts say!

There are plenty of dirt-cheap FTSE 100 banking stocks for investors to choose from today. Our writer Royston Wild believes…

Read more »

Three signposts pointing in different directions, with 'Buy' 'Sell' and 'Hold' on
Investing Articles

Just released: Share Advisor’s latest ‘Hold’ recommendation [PREMIUM PICKS]

In our Share Advisor newsletter service, we provide buy, sell, and hold guidance for our universe of recommendations.

Read more »